SEC Form 4 · accession 0001209191-19-003595
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Tilton
Officer — Chief Commercial Officer
Period of report
Jan 10, 2019
Accepted (ET)
Jan 14, 2019 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jan 10, 2019 | M | 10,500 | $9.29 | A | 10,500 | D | |
| Common SharesF2 | Jan 10, 2019 | S | 10,500 | $37.67 | D | 0 | D | |
| Common Shares | holding | — | — | — | 1,614 | I | By JET Ventures LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $9.29 | Jan 10, 2019 | M | 10,500 | D | — | Dec 14, 2026 | Common Shares | 10,500 | 10,500 | D |
Explanation of responses
- F1The exercise and sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.08 - $37.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3The shares underlying this option vested as to 25% of the shares on December 15, 2016, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date.